OxyChip Implantation and Subsequent Electron Paramagnetic Resonance Oximetry in Human Tumors Is Safe and Feasible : First Experience in 24 Patients

Copyright © 2020 Schaner, Pettus, Flood, Williams, Jarvis, Chen, Pastel, Zuurbier, diFlorio-Alexander, Swartz and Kuppusamy..

Introduction: Tumor hypoxia confers both a poor prognosis and increased resistance to oncologic therapies, and therefore, hypoxia modification with reliable oxygen profiling during anticancer treatment is desirable. The OxyChip is an implantable oxygen sensor that can detect tumor oxygen levels using electron paramagnetic resonance (EPR) oximetry. We report initial safety and feasibility outcomes after OxyChip implantation in a first-in-humans clinical trial (NCT02706197, www.clinicaltrials.gov). Materials and Methods: Twenty-four patients were enrolled. Eligible patients had a tumor ≤ 3 cm from the skin surface with planned surgical resection as part of standard-of-care therapy. Most patients had a squamous cell carcinoma of the skin (33%) or a breast malignancy (33%). After an initial cohort of six patients who received surgery alone, eligibility was expanded to patients receiving either chemotherapy or radiotherapy prior to surgical resection. The OxyChip was implanted into the tumor using an 18-G needle; a subset of patients had ultrasound-guided implantation. Electron paramagnetic resonance oximetry was carried out using a custom-built clinical EPR scanner. Patients were evaluated for associated toxicity using the Common Terminology Criteria for Adverse Events (CTCAE); evaluations started immediately after OxyChip placement, occurred during every EPR oximetry measurement, and continued periodically after removal. The OxyChip was removed during standard-of-care surgery, and pathologic analysis of the tissue surrounding the OxyChip was performed. Results: Eighteen patients received surgery alone, while five underwent chemotherapy and one underwent radiotherapy prior to surgery. No unanticipated serious adverse device events occurred. The maximum severity of any adverse event as graded by the CTCAE was 1 (least severe), and all were related to events typically associated with implantation. After surgical resection, 45% of the patients had no histopathologic findings specifically associated with the OxyChip. All tissue pathology was "anticipated" excepting a patient with greater than expected inflammatory findings, which was assessed to be related to the tumor as opposed to the OxyChip. Conclusion: This report of the first-in-humans trial of OxyChip implantation and EPR oximetry demonstrated no significant clinical pathology or unanticipated serious adverse device events. Use of the OxyChip in the clinic was thus safe and feasible.

Medienart:	E-Artikel

Erscheinungsjahr:	2020
Erschienen:	2020

Enthalten in:	Zur Gesamtaufnahme - volume:10
Enthalten in:	Frontiers in oncology - 10(2020) vom: 28., Seite 572060

Sprache:	Englisch

Beteiligte Personen:	Schaner, Philip E [VerfasserIn] Pettus, Jason R [VerfasserIn] Flood, Ann Barry [VerfasserIn] Williams, Benjamin B [VerfasserIn] Jarvis, Lesley A [VerfasserIn] Chen, Eunice Y [VerfasserIn] Pastel, David A [VerfasserIn] Zuurbier, Rebecca A [VerfasserIn] diFlorio-Alexander, Roberta M [VerfasserIn] Swartz, Harold M [VerfasserIn] Kuppusamy, Periannan [VerfasserIn]

Links:	Volltext

Themen:	Clinical trial Electron paramagnetic resonance Feasibility Hypoxia Journal Article Oximetry OxyChip Safety

Anmerkungen:	Date Revised 24.07.2021 published: Electronic-eCollection ClinicalTrials.gov: NCT02706197 Citation Status PubMed-not-MEDLINE

doi:	10.3389/fonc.2020.572060

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	NLM317620681